Latest:
Trainees Deserve Better Feedback
Feedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ayesha Alvero, MD, MSc
Latest:
Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer Models
Ayesha Alvero, MD, MSc, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.
Laura W. Dillon, PhD, FACMG
Latest:
Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML
The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.
Ryan Scott
Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages
Latest:
Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST
The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.
The US Oncology Network
Latest:
The US Oncology Network Expands its Tennessee Service Area as Tennessee Cancer Specialists Joins The Network
Tennessee Cancer Specialists, the third largest oncology practice in the state, strengthens its ability to deliver cutting-edge advanced care by joining The Network.
Christopher Wee, MD
Latest:
Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and Classification
Christopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.
Mark Levis, MD, PhD, Johns Hopkins University School of Medicine
Latest:
Treatment Approaches for TP53-Mutated AML
Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.
Neil H. Bander, MD
Latest:
Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPC
Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.